| | □特定对象调研□分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访√业绩说明会 | | 类别 | □新闻发布会□路演活动 | | | □现场参观□电话会议 | | | □其他：（请文字说明其他活动内容） | | 参与单位名称 | *ST恒久2024年度业绩说明会采用网络远程方式进行，面向全体投资者 | | 及人员姓名 | | | 时间 | 年 5 月 19 日 15:00-17:00 2025 | | 地点 | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 | | 公司接待人员 | 主持人：*ST恒久 | | | 董事长：余荣清 | | 姓名 | 董秘：张冬云 | | | 财务负责人：冯芬兰 | | | 独立董事：林开涛 | | | 1.高管您好，请问您如何看待行业未来的发展前景？谢谢。 | | | 答：您好，影像产业，由于目前打印与复印和印刷产业三者已日益 | | | 融合，并且在国家信创政策的驱动下，国产整机已获得突破，因此在可 | | | 见的未来，国产整机产业在满足日益扩大的国内市场，已开始在国际市 | | 投资者关系活 ...

Core Viewpoint - The Guizhou International Energy Industry Expo has highlighted Brother (China)'s significant contributions to the energy and power sector through innovative identification solutions aimed at enhancing safety, standardization, and intelligence in the industry [1][7]. Group 1: Product Innovations - Brother (China) showcased its industrial-grade identification management solutions, which include cable identification and switch management systems, as well as fixed asset management solutions designed for outdoor construction and asset management [3]. - The Brother P-Touch color tape, designed for extreme environments, features waterproof, oil-resistant, high and low-temperature resistance, strong adhesion, wear resistance, and corrosion resistance, making it suitable for various applications such as coal mines, power rooms, and new energy power stations [3]. - The company also presented high-visibility and durable safety warning signs that play a crucial role in job sites, enhancing safety management and providing clear instructions and warnings to workers, thereby improving operational efficiency [5]. Group 2: Engagement and Future Plans - The expo provided Brother (China) with an opportunity to demonstrate its leading position in professional identification solutions for the energy and power industry while engaging in in-depth exchanges and collaborations with industry peers [7]. - The company aims to continue its commitment to innovation, contributing further to the safety, standardization, and intelligent upgrades in the energy and power sector [7].

证券研究报告·A 股公司简评 计算机 核心观点 2024 年，公司营收 264.15 亿元，同比增长 9.78%；归母净利润 7.49 亿元，同比增长 112.11%；扣非归母净利润 3.53 亿元，同比 增长 105.60%。25Q1，公司营收 59.27 亿元，同比下降 5. 79%； 归母净利润 0.84 亿元，同比下降 69.64%。受益于国内信创打印 机出货持续增长，一带一路推动下海外需求旺盛，叠加公司 A 3 打 印机销量实现高速增长，预计公司 2025-2027 年营业收入分别为 156.76/193.94/237.53 亿元，同比分别变动-40.65%/23.72%/ 22.48%，归母净利润为 15.60/22.12/29.90 亿元，同比分别增长 108.28%/41.73%/35.21%，对应 PE 20/14/10 倍，维持"买入"评 级。 事件 2024 年，公司营收 264.15 亿元，同比增长 9.78%；归母净利润 7.49 亿元，同比增长 112.11%；扣非归母净利润 3.53 亿元，同比 增长 105.60%。2025 年第一季度，公司营收 59.27 亿元，同比下 降 ...

25Q1 受市场采购节奏影响经营承压，毛利率持续提高。2025 年第一季度，纳思达营收59.27 亿元，同 比下降5.79%；归母净利润0.84 亿元，同比下降69.64%；受市场采购节奏影响相对承压；毛利率则逆市 同比提升0.48pct 至31.70%；销售/管理/研发/财务费用率分别变动-0.41/-0.36/-0.04/+1.09pct，汇兑损益和 未确认融资费用增加导致财务费用提升。 分业务看，24 年打印及耗材业务平稳增长，25Q1 各业务普遍承压。 核心观点 2024 年，公司营收264.15 亿元，同比增长9.78%；归母净利润7.49 亿元，同比增长112.11%；扣非归母 净利润3.53 亿元，同比增长105.60%。25Q1，公司营收59.27 亿元，同比下降5. 79%；归母净利润0.84 亿元，同比下降69.64%。受益于国内信创打印机出货持续增长，一带一路推动下海外需求旺盛，叠加 公司A3 打印机销量实现高速增长，预计公司2025-2027 年营业收入分别为156.76/193.94/237.53 亿元， 同比分别变动-40.65%/23.72%/22.48%，归母净利润为15.60 ...

海关系统2025年 4 ~ 9 月 仪器设备采购 意向汇总表 | | | 预 | | | --- | --- | --- | --- | | 采购 | 需求概况 | 算 | 采购 | | 项目 | | 万 | 时间 | | | | 元 | | | 湖南 | | | | | 国际 | | | | | 旅行 | | | | | 卫生 | | | | | 保健 | | | | | 中心 | | | | | （长 | | | | | 沙海 | | | | | 关口 | 为提升长沙海关口岸科技支撑能力，提升实验室检测现代化、规范化 | | 2025 | | 岸门 | | 832 | 年6 | | 诊 | 能力，拟更新超期服役、故障率高的老旧仪器设备。 | | 月 | | 部） | | | | | 2025 | | | | | 年实 | | | | | 验室 | | | | | 仪器 | | | | | 设备 | | | | | 更新 | | | | | 项目 | | | | | 海科 | 采购1台超低本底液体闪烁谱仪，用于样品中低能β放射性核素、a放射 | 160 | 2025 | | 中心 | 性核素的活度测量，具备 ...

Investment Rating - The report does not explicitly state an investment rating for the experimental-grade silica gel matrix chromatography filler industry Core Insights - The report focuses on the experimental-grade silica gel matrix chromatography filler industry, highlighting the significant growth potential driven by the rapid development of the peptide active pharmaceutical ingredient market and the increasing demand for chromatographic materials in the pharmaceutical sector [4][22] - Key factors driving market growth include technological innovation and the trend towards domestic production, with the domestic production rate expected to rise from approximately 40% to 60% by 2030 [4][13] Industry Overview - The experimental-grade silica gel matrix chromatography filler is primarily used for laboratory analysis of organic compounds, natural products, and peptides, with applications in pharmaceutical quality analysis, food safety testing, environmental monitoring, and chemical research [5][22] - The industry is characterized by a low domestic replacement rate but a rapid pace of domestic production development, with significant contributions from both international and domestic companies [9][13] Market Dynamics - The upstream market is dominated by international chemical companies, while the midstream filler preparation market is led by overseas firms, with a current domestic production rate of about 40% [21][29] - The downstream applications are diverse, with the pharmaceutical industry being the primary demand driver, particularly due to the growth in the peptide drug market [22][32] Competitive Landscape - The market is currently fragmented, with major international players like GE, Agilent, and Waters holding significant market shares, while domestic companies are still developing their presence [40][41] - The report indicates a trend towards market concentration as domestic firms innovate and respond to cost control demands from pharmaceutical companies [43] Market Size and Growth Forecast - The global market for experimental-grade silica gel matrix chromatography fillers is projected to grow from approximately 2.15 billion yuan in 2024 to 2.81 billion yuan by 2030, with a compound annual growth rate (CAGR) of 4.5% [33][36] - The Chinese market is expected to expand from around 500 million yuan in 2024 to 900 million yuan by 2030, reflecting a CAGR of 10.3% [33][36] Policy Environment - The report outlines several supportive policies aimed at promoting the development of high-end chromatography technologies and materials, which are expected to further stimulate market growth [38][39]

证 券 研 究 报 告 盈利能力复苏，拐点初现 医药生物行业2024年报暨25Q1季报总结 证券分析师：张静含 A0230522080004 研究支持：李敏杰 A0230523070006 2025.5.16 投资案件 www.swsresearch.com 证券研究报告 2 ◼ 整体业绩表现：2024年473家沪深两市A股医药上市公司实现营业总收入24,588亿元， 同比下降0.9%，实现归母净利润1,412亿元，同比下降12.1%。25Q1板块实现营业总 收入6,104亿元，同比下降4.2%，实现归母净利润487亿元，同比下降8.7%，去除 24Q1大额BD的基数扰动，25Q1板块归母净利润同比增长0.7%，净利润率也有 0.3%的提升，这是医药板块在经历了三年盈利能力下行后首次出现利润率反转的迹象。 ◼ 子板块及个股业绩亮点：一季度业绩表现较好的子板块包括CXO、创新药、生物制品、 民营医院、医疗耗材等。CXO板块从24Q4起业绩底部反转，创新药板块收入持续保持 高增长。同时值得注意的是，一季度有多家头部公司业绩超预期，如药明康德、恒瑞 医药、百济神州、爱尔眼科、华兰生物、甘李药业、益丰药房、大参林、云 ...

Group 1 - China State Construction signed new contracts totaling 1.52 trillion yuan from January to April, representing a year-on-year increase of 2.8% [1] - Yongpu Medical's subsidiary obtained a medical device business license valid until May 7, 2030, allowing it to engage in medical device retail and wholesale [1] - Ningbo Maritime received a government subsidy of 4.42 million yuan, which will impact its net profit for the fiscal year 2025 [1] Group 2 - Mingpu Optoelectronics obtained a patent for a magnetic powder core and its preparation method, enhancing its capabilities in magnetic materials technology [1] - Digital Zhitong plans to establish a wholly-owned subsidiary in Beijing with a registered capital of 5 million yuan [1] - Zhongmin Energy's shareholder plans to reduce its stake by up to 0.28% of the company's total shares [1][6] Group 3 - Tunnel Holdings' controlling shareholder intends to increase its stake in the company by investing between 250 million to 500 million yuan [1] - China Telecom appointed Liu Guiqing as the new President and COO [1] - Datang Power completed the issuance of 3 billion yuan in medium-term notes, with proceeds aimed at repaying debt and supplementing working capital [1] Group 4 - *ST Weihai won a bid for a flood control project worth 182 million yuan, accounting for 7.35% of its audited revenue for 2024 [1] - Huijin Tong announced a cash dividend of 0.0868 yuan per share, totaling 29.44 million yuan [1] - Xinkai Energy's shareholders plan to reduce their holdings by a combined total of 4% of the company's shares [1][39] Group 5 - Xinhuan Group's subsidiary won a 1.02 billion yuan nuclear power project contract [1] - Southern Airlines reported a 12.14% year-on-year increase in passenger turnover for April [1] - Xinjiang Torch plans to acquire 100% equity of Yushan Litai for 125 million yuan [1]

Group 1 - Lingyun Optics' actual controller promises not to reduce shareholdings for 12 months starting from July 7, 2025 [1] - Chengdi Xiangjiang's subsidiary signed a contract with China Mobile for a data center project worth 1.632 billion yuan, with a 92-day construction period starting April 30, 2025 [1] - Dingyang Technology launched a high-end arbitrary waveform generator with a maximum output frequency of 5 GHz, catering to communication, industrial, and research testing needs [2][3] Group 2 - Heng Rui Medicine completed a share repurchase plan, buying back 12.9051 million shares for 601 million yuan, representing 0.20% of total shares [4][5] - ST Xiangxue received approval for clinical trials of TAEST1901 injection for treating advanced gastric cancer [5] - Yuyue Medical's subsidiary received EU MDR certification for its AED product, valid until May 11, 2030 [6][7] Group 3 - HNA Holding reported a 10.33% year-on-year increase in passenger revenue kilometers for April [8] - Springhui Zhikong's subsidiary terminated its listing on the National Equities Exchange and Quotations [9] - Delin Hai's shareholder plans to reduce holdings by up to 3%, equating to 3.39 million shares [10] Group 4 - Weiye Co. announced that two shareholders plan to reduce their holdings by up to 2% [12] - Green Alliance Technology's major shareholder intends to reduce holdings by up to 3% [14] - Luzhou Development Group increased its stake in Luzhou Tianhua by 1.02%, acquiring 15.9557 million shares [16] Group 5 - Hualan Pharmaceutical's subsidiary plans to acquire a 42.82% stake in Sanjing Qianhe for 23.446 million yuan [17] - Ganfeng Lithium's directors and executives plan to invest 30.8 million yuan in Shenzhen Yichu [19] - Zhonghong Medical's subsidiary is expected to be selected for a centralized procurement project [20] Group 6 - Jinkai Biotechnology's Blue Zone Fund plans to reduce holdings by up to 3% [21] - Hangxin Technology's former controlling shareholder intends to reduce holdings by up to 3% [22] - Galaxy Magnet's director plans to reduce holdings by up to 0.79% [23] Group 7 - Zhuoyue Technology's controlling shareholder's shares will be auctioned due to judicial proceedings [24] - Xinwufeng is forming a joint venture with France's Coplison Group with a registered capital of 80 million yuan [25] - Zhongcheng Co. is planning to issue shares to acquire 100% of a clean energy company, leading to a temporary stock suspension [26][27]

Core Viewpoint - Zhonghong Medical's subsidiary, Kelong Medical, is set to be selected for the volume-based procurement project for medical consumables in the central region of Xinjiang Uygur Autonomous Region, which will prioritize the use of its products in local medical institutions [1] Group 1 - Zhonghong Medical announced that Kelong Medical participated in the second batch of volume-based procurement for medical consumables in the central alliance of Xinjiang Uygur Autonomous Region [1] - The selected products include disposable vacuum blood collection tubes and disposable venous blood sampling needles [1] - During the procurement period, medical institutions in the procurement area will give priority to using the products proposed for selection by the company [1]